{"id":"W2168391786","doi":"10.2174/092986706779026174","title":"Targeting the EGFR Pathway for Cancer Therapy","year":2006,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Strong; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Cetuximab; Medicine; Gefitinib; Panitumumab; Pertuzumab; Lapatinib; Erlotinib; Amphiregulin; Epidermal growth factor receptor; Lung cancer; Targeted therapy; Trastuzumab; Cancer; Cancer research; Breast cancer; Epidermal growth factor; Oncology; Internal medicine; Colorectal cancer; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002544507,0.0005900143,0.0005492595,0.0008331708,0.0001869427,0.0007720212,0.000512422,0.001068394,0.008880743],"category_scores_gemma":[0.0002147051,0.0001286633,0.0004191024,0.0005445321,0.0003208163,0.0008786254,0.0006349576,0.002165714,0.004729549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007762468,"about_ca_system_score_gemma":0.0004734692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004303576,"about_ca_topic_score_gemma":0.0008571763,"domain_scores_codex":[0.9998173,0.00003184934,0.00001254528,0.00003836411,0.00007251107,0.00002749321],"domain_scores_gemma":[0.9999396,0.00001745716,0.00001148701,0.000004394106,0.00001765782,0.000009508291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001222726,0.0001197011,0.0001596224,0.005217055,0.00007414874,0.0003877508,0.00007416974,0.0008249076,0.02103741,0.01764371,0.0730963,0.8812431],"study_design_scores_gemma":[0.00001605017,0.0001049042,0.0002505922,0.0006277665,0.00003341477,0.0009995106,0.0000163089,0.0002002987,0.002266098,0.003115713,0.9923584,0.00001101215],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007789789,0.9826396,0.001600012,0.002013846,0.0009660454,0.00001987307,0.00007343874,0.00006094664,0.01184734],"genre_scores_gemma":[0.0110095,0.9648997,0.001618618,0.001993156,0.001145592,0.00003800276,0.0001902463,0.00001718372,0.01908818],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008880743,"threshold_uncertainty_score":0.02970904,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1949928734727937,"score_gpt":0.4903576461793562,"score_spread":0.2953647727065626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}